These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 7795270

  • 1. A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.
    Brown TD, Fleming TR, Goodman PJ, Macdonald JS, Pugh RP, O'Rourke T.
    Anticancer Drugs; 1995 Apr; 6(2):219-23. PubMed ID: 7795270
    [Abstract] [Full Text] [Related]

  • 2. Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
    Bowen D, Johnson DH, Southerland WM, Hughes DE, Hawkins M.
    Anticancer Res; 1999 Apr; 19(5B):3837-40. PubMed ID: 10628320
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study.
    Fleming TR, Brown TD, Ross SW, Macdonald JS.
    Invest New Drugs; 1996 Apr; 13(4):363-5. PubMed ID: 8824358
    [Abstract] [Full Text] [Related]

  • 4. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, Schilsky R, Fleagle J, Moore M, Kemeny N, Carlin D, Hammershaimb L, Haller D.
    Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
    [Abstract] [Full Text] [Related]

  • 5. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA, Kemeny N, Seiter K, Goker E, Tong W, André M, Ragusa K, Bertino JR.
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
    Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M.
    J Clin Oncol; 1997 Mar; 15(3):915-20. PubMed ID: 9060528
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ, European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    J Clin Oncol; 2003 Oct 15; 21(20):3721-8. PubMed ID: 12963704
    [Abstract] [Full Text] [Related]

  • 8. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H, Hohenberger P, Lochs H, Haboubi N, Berdel WE, Thiel E, Kreuser ED.
    Oncology; 2000 May 15; 58(4):273-9. PubMed ID: 10838491
    [Abstract] [Full Text] [Related]

  • 9. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D, Southerland WM, Johnson DH, Hawkins M, Hughes DE.
    Cancer Detect Prev; 2000 May 15; 24(5):452-8. PubMed ID: 11129987
    [Abstract] [Full Text] [Related]

  • 10. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH.
    Cancer; 1998 Jan 15; 82(2):292-300. PubMed ID: 9445185
    [Abstract] [Full Text] [Related]

  • 11. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E, Heike M, Bernhard H, Klein O, Bernhard G, Lautz D, Michaelis J, Meyer zum Büschenfelde KH, Knuth A.
    J Clin Oncol; 1996 Aug 15; 14(8):2274-9. PubMed ID: 8708717
    [Abstract] [Full Text] [Related]

  • 12. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E, Beuzeboc P, Deffontaines D, Diéras V, Dorval T, Jouve M, Palangie T, Scholl S, Pouillart P.
    J Infus Chemother; 1996 Aug 15; 6(3):149-51. PubMed ID: 9229328
    [Abstract] [Full Text] [Related]

  • 13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS, Mangalik A, Ferguson J, Elias L.
    Clin Cancer Res; 1995 Jun 15; 1(6):615-20. PubMed ID: 9816023
    [Abstract] [Full Text] [Related]

  • 14. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
    Abad A, Garcia P, Gravalos C, Tusquets I, Font A, Perez G, Cortés-Funes H, Fabregat X, Barnadas A, Rosell R.
    Cancer; 1995 Mar 15; 75(6):1238-44. PubMed ID: 7882275
    [Abstract] [Full Text] [Related]

  • 15. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD, Messenger M, Taplin SC.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [Abstract] [Full Text] [Related]

  • 16. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A, Tsavaris N, Giannopoulos A, Bacoyiannis C, Papadimas V, Kalahanis N, Karatzas G, Kosmas C, Sakelaropoulos N, Archimandritis A, Papachristodoulou A, Kosmidis P.
    Cancer Chemother Pharmacol; 1996 Oct 15; 38(3):292-7. PubMed ID: 8646806
    [Abstract] [Full Text] [Related]

  • 17. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    Machiavelli MR, Salum G, Pérez JE, Ortiz EH, Romero AO, Bologna F, Vallejo CT, Lacava JA, Dominguez ME, Leone BA.
    Am J Clin Oncol; 2004 Apr 15; 27(2):149-54. PubMed ID: 15057154
    [Abstract] [Full Text] [Related]

  • 18. A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
    Matin K, Jacobs SA, Richards T, Wong MK, Earle M, Evans T, Troetschel M, Ferri W, Friedland D, Pinkerton R, Volkin R, Wieand S, Ramanathan RK.
    Am J Clin Oncol; 2005 Oct 15; 28(5):439-44. PubMed ID: 16199980
    [Abstract] [Full Text] [Related]

  • 19. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Lévi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L.
    J Natl Cancer Inst; 1994 Nov 02; 86(21):1608-17. PubMed ID: 7932825
    [Abstract] [Full Text] [Related]

  • 20. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Valone FH, Friedman MA, Wittlinger PS, Drakes T, Eisenberg PD, Malec M, Hannigan JF, Brown BW.
    J Clin Oncol; 1989 Oct 02; 7(10):1427-36. PubMed ID: 2789272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.